Phase 1b trial is designed to evaluate safety, tolerability, and efficacy of potent Kv1.3 blocker in T-cell mediated autoimmunity – San Diego, CA, USA, and Munich, Germany – September 12, 2022 – selectION, Inc., a clinical-stage biopharmaceutical company developing novel…